Galderma presented new data on Nemluvio, a treatment for atopic dermatitis and prurigo nodularis, showing deep and lasting skin lesion and itch responses in patients aged 12 and older.
Key points
•Nemluvio maintained deep and lasting skin lesion and itch responses for up to three years
•New post-hoc data from ARCADIA LTE study showed consistent safety and efficacy
•Pediatric phase II data supported Nemluvio's effectiveness in children aged 2-11 years
The company announced that the majority of Week 16 responders maintained significant improvements after three years. This data comes from the ARCADIA long-term extension (LTE) study, which evaluated Nemluvio's efficacy and safety over an extended period in adults and adolescents with moderate-to-severe atopic dermatitis.
Additional analyses showed consistent safety profiles and sustained efficacy for up to 148 weeks in people with prurigo nodularis. The data also highlighted improvements in skin clearance, itch, sleep, and quality of life among participants aged 12 and older. Pediatric phase II data demonstrated meaningful and sustained improvements in children aged 2-11 years.
These findings support Galderma's leadership in advancing treatment goals for atopic dermatitis and prurigo nodularis, with Nemluvio showing deep and lasting responses across various patient populations.
